VAX-31 – Talk Bio

Vaxcyte Strikes up to $1B Fill-Finish Manufacturing Deal with Thermo Fisher at North Carolina Facility

3 weeks ago talkbio0Tagged biomanufacturing, commercial supply chain, Manufacturing, North Carolina, PCVs, pneumococcal conjugate vaccines, production, Thermo Fisher Scientific, United States, Vaccines, VAX-24, VAX-31, Vaxcyte

Vaxcyte; Thermo Fisher Scientific; fill-finish manufacturing; North Carolina; pneumococcal conjugate vaccines; PCVs; VAX-31; VAX-24; commercial supply chain; biomanufacturing; U.S. vaccine production; $1 billion deal

Vaxcyte Announces Positive Phase 1/2 Results for VAX-31, Advances to Phase 3

1 year ago talkbio0Tagged Bacterial Infections, development aspects, Phase 3 program, pneumococcal conjugate, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, pneumococcal conjugate vaccine, Phase 1/2 study, Phase 3 program, vaccine development, bacterial diseases

Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results

1 year ago talkbio0Tagged development aspects, Invasive Streptococcus pneumoniae disease, Phase 3 trials, Pneumococcal vaccine, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development